{"entity":{"id":"tqb2922","kind":"drug","name":"TQB2922","aka":[],"tldr":"TQB2922 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 2 trials for colorectal cancer, aimed at EGFR and MET.","summary":"TQB2922 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: TQB2922 is an anti-EGFR/c-Met bispecific IgG1 antibody that blocks EGFR and c-Met signalling by binding both receptors on tumour cells and engages antibody-dependent cellular cytotoxicity and phagocytosis via NK cells and macrophages. ClinicalTrials.gov describes the intervention as: TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07044908, plans to enrol 72 participants with primary completion was scheduled for 2026-07 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TQB2922","url":"https://clinicaltrials.gov/search?intr=TQB2922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07044908"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"TQB2922 is an anti-EGFR/c-Met bispecific IgG1 antibody that blocks EGFR and c-Met signalling by binding both receptors on tumour cells and engages antibody-dependent cellular cytotoxicity and phagocytosis via NK cells and macrophages.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tqb2922/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct07044908","kind":"trial","name":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct07044908/"}]}}